Item 2.02 Results of Operations and Financial Condition. On November 11, 2026, OptimizeRx Corporation (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2026 and updated 2026 revenue guidance. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.…
Filed Nov 13, 2026Accepted Nov 13, 2026, 4:06 PM ESTCIK 1448431Accession 0001448431-26-000022
OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On November 11, 2026, OptimizeRx Corporation (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2026 and updated 2026 revenue guidance. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
On November 11, 2026, the Company hosted an investor conference call to discuss items in its November 11, 2026 press release in more detail and to allow the investment community an opportunity to ask questions. A copy of the transcript from the conference call is furnished with this Current Report on Form 8-K as Exhibit 99.2 and is incorporated herein by reference.
The information in this Item 2.02, including Exhibit 99.1 and Exhibit 99.2 attached hereto, are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.